1 Report Overview 1.1 Research Scope 1.2 Market Segment by Type 1.2.1 Global Idiopathic Pulmonary Fibrosis Drug Market Size Growth Rate by Type (2017 VS 2021 VS 2028) 1.2.2 Glucocorticoid 1.2.3 Immunosuppressive Agent 1.2.4 Others 1.3 Market Segment by Application 1.3.1 Global Idiopathic Pulmonary Fibrosis Drug Market Share by Application (2017 VS 2021 VS 2028) 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Market Perspective 2.1 Global Idiopathic Pulmonary Fibrosis Drug Market Size (2017-2028) 2.1.1 Global Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) 2.1.2 Global Idiopathic Pulmonary Fibrosis Drug Sales (2017-2028) 2.2 Global Idiopathic Pulmonary Fibrosis Drug Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028 2.2.1 Global Idiopathic Pulmonary Fibrosis Drug Sales by Regions (2017-2022) 2.2.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue by Regions (2017-2022) 2.3 Global Idiopathic Pulmonary Fibrosis Drug Market Size Forecast by Region 2.3.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Forecast by Region (2023-2028) 2.3.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue Forecast by Region (2023-2028) 2.4 Global Top Idiopathic Pulmonary Fibrosis Drug Regions (Countries) Ranking by Market Size 2.5 Idiopathic Pulmonary Fibrosis Drug Market Dynamics 2.5.1 Idiopathic Pulmonary Fibrosis Drug Market Trends 2.5.2 Idiopathic Pulmonary Fibrosis Drug Market Drivers 2.5.3 Idiopathic Pulmonary Fibrosis Drug Market Challenges 2.5.4 Idiopathic Pulmonary Fibrosis Drug Market Restraints 3 Competitive Landscape by Manufacturers 3.1 Global Top Idiopathic Pulmonary Fibrosis Drug Manufacturers by Sales (2017-2022) 3.1.1 Global Idiopathic Pulmonary Fibrosis Drug Sales by Manufacturers (2017-2022) 3.1.2 Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global 5 and 10 Largest Manufacturers by Idiopathic Pulmonary Fibrosis Drug Sales in 2021 3.2 Global Top Manufacturers Idiopathic Pulmonary Fibrosis Drug by Revenue 3.2.1 Global Idiopathic Pulmonary Fibrosis Drug Revenue by Manufacturers (2017-2022) 3.2.2 Top Idiopathic Pulmonary Fibrosis Drug Manufacturers Covered: Ranking by Revenue 3.2.3 Global Idiopathic Pulmonary Fibrosis Drug Revenue Share by Manufacturers (2017-2022) 3.2.4 Global Idiopathic Pulmonary Fibrosis Drug Market Concentration Ratio (CR5 and HHI) 3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis Drug as of 2021) 3.4 Global Idiopathic Pulmonary Fibrosis Drug Average Selling Price (ASP) by Manufacturers 3.5 Key Manufacturers Idiopathic Pulmonary Fibrosis Drug Plants/Factories Distribution and Area Served 3.6 Date of Key Manufacturers Enter into Idiopathic Pulmonary Fibrosis Drug Market 3.7 Key Manufacturers Idiopathic Pulmonary Fibrosis Drug Product Offered 3.8 Mergers & Acquisitions, Expansion Plans 4 Global Idiopathic Pulmonary Fibrosis Drug Market Size by Type 4.1 Global Idiopathic Pulmonary Fibrosis Drug Historic Market Review by Type (2017-2022) 4.1.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2017-2022) 4.1.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Type (2017-2022) 4.1.3 Idiopathic Pulmonary Fibrosis Drug Price by Type (2017-2022) 4.2 Global Idiopathic Pulmonary Fibrosis Drug Market Estimates and Forecasts by Type (2023-2028) 4.2.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Forecast by Type (2023-2028) 4.2.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue Forecast by Type (2023-2028) 4.2.3 Idiopathic Pulmonary Fibrosis Drug Price Forecast by Type (2023-2028) 5 Global Idiopathic Pulmonary Fibrosis Drug Market Size by Application 5.1 Global Idiopathic Pulmonary Fibrosis Drug Historic Market Review by Application (2017-2022) 5.1.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2017-2022) 5.1.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Application (2017-2022) 5.1.3 Idiopathic Pulmonary Fibrosis Drug Price by Application (2017-2022) 5.2 Global Idiopathic Pulmonary Fibrosis Drug Market Estimates and Forecasts by Application (2023-2028) 5.2.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Forecast by Application (2023-2028) 5.2.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue Forecast by Application (2023-2028) 5.2.3 Idiopathic Pulmonary Fibrosis Drug Price Forecast by Application (2023-2028) 6 North America 6.1 North America Idiopathic Pulmonary Fibrosis Drug Sales Breakdown by Company 6.1.1 North America Idiopathic Pulmonary Fibrosis Drug Sales by Company (2017-2022) 6.1.2 North America Idiopathic Pulmonary Fibrosis Drug Revenue by Company (2017-2022) 6.2 North America Idiopathic Pulmonary Fibrosis Drug Market Size by Type 6.2.1 North America Idiopathic Pulmonary Fibrosis Drug Sales by Type (2017-2028) 6.2.2 North America Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2017-2028) 6.3 North America Idiopathic Pulmonary Fibrosis Drug Market Size by Application 6.3.1 North America Idiopathic Pulmonary Fibrosis Drug Sales by Application (2017-2028) 6.3.2 North America Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2017-2028) 6.4 North America Idiopathic Pulmonary Fibrosis Drug Market Size by Country 6.4.1 North America Idiopathic Pulmonary Fibrosis Drug Sales by Country (2017-2028) 6.4.2 North America Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2017-2028) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe Idiopathic Pulmonary Fibrosis Drug Sales Breakdown by Company 7.1.1 Europe Idiopathic Pulmonary Fibrosis Drug Sales by Company (2017-2022) 7.1.2 Europe Idiopathic Pulmonary Fibrosis Drug Revenue by Company (2017-2022) 7.2 Europe Idiopathic Pulmonary Fibrosis Drug Market Size by Type 7.2.1 Europe Idiopathic Pulmonary Fibrosis Drug Sales by Type (2017-2028) 7.2.2 Europe Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2017-2028) 7.3 Europe Idiopathic Pulmonary Fibrosis Drug Market Size by Application 7.3.1 Europe Idiopathic Pulmonary Fibrosis Drug Sales by Application (2017-2028) 7.3.2 Europe Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2017-2028) 7.4 Europe Idiopathic Pulmonary Fibrosis Drug Market Size by Country 7.4.1 Europe Idiopathic Pulmonary Fibrosis Drug Sales by Country (2017-2028) 7.4.2 Europe Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2017-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 8 Asia Pacific 8.1 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales Breakdown by Company 8.1.1 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales by Company (2017-2022) 8.1.2 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue by Company (2017-2022) 8.2 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Market Size by Type 8.2.1 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales by Type (2017-2028) 8.2.2 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2017-2028) 8.3 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Market Size by Application 8.3.1 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales by Application (2017-2028) 8.3.2 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2017-2028) 8.4 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Market Size by Region 8.4.1 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales by Region 8.4.2 Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue by Region 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 India 8.4.7 Australia 8.4.8 Taiwan 8.4.9 Indonesia 8.4.10 Thailand 8.4.11 Malaysia 8.4.12 Philippines 8.4.13 Vietnam 9 Latin America 9.1 Latin America Idiopathic Pulmonary Fibrosis Drug Sales Breakdown by Company 9.1.1 Latin America Idiopathic Pulmonary Fibrosis Drug Sales by Company (2017-2022) 9.1.2 Latin America Idiopathic Pulmonary Fibrosis Drug Revenue by Company (2017-2022) 9.2 Latin America Idiopathic Pulmonary Fibrosis Drug Market Size by Type 9.2.1 Latin America Idiopathic Pulmonary Fibrosis Drug Sales by Type (2017-2028) 9.2.2 Latin America Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2017-2028) 9.3 Latin America Idiopathic Pulmonary Fibrosis Drug Market Size by Application 9.3.1 Latin America Idiopathic Pulmonary Fibrosis Drug Sales by Application (2017-2028) 9.3.2 Latin America Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2017-2028) 9.4 Latin America Idiopathic Pulmonary Fibrosis Drug Market Size by Country 9.4.1 Latin America Idiopathic Pulmonary Fibrosis Drug Sales by Country (2017-2028) 9.4.2 Latin America Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2017-2028) 9.4.3 Mexico 9.4.4 Brazil 9.4.5 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales Breakdown by Company 10.1.1 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales by Company (2017-2022) 10.1.2 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue by Company (2017-2022) 10.2 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Market Size by Type 10.2.1 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales by Type (2017-2028) 10.2.2 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2017-2028) 10.3 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Market Size by Application 10.3.1 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales by Application (2017-2028) 10.3.2 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2017-2028) 10.4 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Market Size by Country 10.4.1 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales by Country (2017-2028) 10.4.2 Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2017-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 U.A.E 11 Company Profiles 11.1 Roche 11.1.1 Roche Corporation Information 11.1.2 Roche Overview 11.1.3 Roche Idiopathic Pulmonary Fibrosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.1.4 Roche Idiopathic Pulmonary Fibrosis Drug Products and Services 11.1.5 Roche Idiopathic Pulmonary Fibrosis Drug SWOT Analysis 11.1.6 Roche Recent Developments 11.2 Boehringer Ingelheim 11.2.1 Boehringer Ingelheim Corporation Information 11.2.2 Boehringer Ingelheim Overview 11.2.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.2.4 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Drug Products and Services 11.2.5 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Drug SWOT Analysis 11.2.6 Boehringer Ingelheim Recent Developments 11.3 Beijing Continent Pharmaceutical 11.3.1 Beijing Continent Pharmaceutical Corporation Information 11.3.2 Beijing Continent Pharmaceutical Overview 11.3.3 Beijing Continent Pharmaceutical Idiopathic Pulmonary Fibrosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.3.4 Beijing Continent Pharmaceutical Idiopathic Pulmonary Fibrosis Drug Products and Services 11.3.5 Beijing Continent Pharmaceutical Idiopathic Pulmonary Fibrosis Drug SWOT Analysis 11.3.6 Beijing Continent Pharmaceutical Recent Developments 11.4 Cipla 11.4.1 Cipla Corporation Information 11.4.2 Cipla Overview 11.4.3 Cipla Idiopathic Pulmonary Fibrosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.4.4 Cipla Idiopathic Pulmonary Fibrosis Drug Products and Services 11.4.5 Cipla Idiopathic Pulmonary Fibrosis Drug SWOT Analysis 11.4.6 Cipla Recent Developments 11.5 Shionogi 11.5.1 Shionogi Corporation Information 11.5.2 Shionogi Overview 11.5.3 Shionogi Idiopathic Pulmonary Fibrosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.5.4 Shionogi Idiopathic Pulmonary Fibrosis Drug Products and Services 11.5.5 Shionogi Idiopathic Pulmonary Fibrosis Drug SWOT Analysis 11.5.6 Shionogi Recent Developments 12 Value Chain and Sales Channels Analysis 12.1 Idiopathic Pulmonary Fibrosis Drug Value Chain Analysis 12.2 Idiopathic Pulmonary Fibrosis Drug Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Idiopathic Pulmonary Fibrosis Drug Production Mode & Process 12.4 Idiopathic Pulmonary Fibrosis Drug Sales and Marketing 12.4.1 Idiopathic Pulmonary Fibrosis Drug Sales Channels 12.4.2 Idiopathic Pulmonary Fibrosis Drug Distributors 12.5 Idiopathic Pulmonary Fibrosis Drug Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.2 Data Source 14.2 Author Details 14.3 Disclaimer

List of Tables Table 1. Global Idiopathic Pulmonary Fibrosis Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million) Table 2. Major Manufacturers of Glucocorticoid Table 3. Major Manufacturers of Immunosuppressive Agent Table 4. Major Manufacturers of Others Table 5. Global Idiopathic Pulmonary Fibrosis Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million) Table 6. Global Idiopathic Pulmonary Fibrosis Drug Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028 Table 7. Global Idiopathic Pulmonary Fibrosis Drug Sales by Region (2017-2022) & (K MT) Table 8. Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Region (2017-2022) Table 9. Global Idiopathic Pulmonary Fibrosis Drug Revenue by Region (2017-2022) & (US$ Million) Table 10. Global Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Region (2017-2022) Table 11. Global Idiopathic Pulmonary Fibrosis Drug Sales Forecast by Region (2023-2028) & (K MT) Table 12. Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share Forecast by Region (2023-2028) Table 13. Global Idiopathic Pulmonary Fibrosis Drug Revenue Forecast by Region (2023-2028) & (US$ Million) Table 14. Global Idiopathic Pulmonary Fibrosis Drug Revenue Market Share Forecast by Region (2023-2028) Table 15. Top Idiopathic Pulmonary Fibrosis Drug Regions (Countries) Ranking by Market Size (US$ Million) in 2021 Table 16. Idiopathic Pulmonary Fibrosis Drug Market Trends Table 17. Idiopathic Pulmonary Fibrosis Drug Market Drivers Table 18. Idiopathic Pulmonary Fibrosis Drug Market Challenges Table 19. Idiopathic Pulmonary Fibrosis Drug Market Restraints Table 20. Global Idiopathic Pulmonary Fibrosis Drug Sales by Manufacturers (2017-2022) & (K MT) Table 21. Global Idiopathic Pulmonary Fibrosis Drug Sales Share by Manufacturers (2017-2022) Table 22. Global Idiopathic Pulmonary Fibrosis Drug Revenue by Manufacturers (2017-2022) & (US$ Million) Table 23. Ranking of Global Top Idiopathic Pulmonary Fibrosis Drug Manufacturers by Revenue (US$ Million) in 2021 Table 24. Idiopathic Pulmonary Fibrosis Drug Revenue Share by Manufacturers (2017-2022) Table 25. Global Idiopathic Pulmonary Fibrosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI) Table 26. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis Drug as of 2021) Table 27. Key Manufacturers Idiopathic Pulmonary Fibrosis Drug Average Selling Price (ASP) & (2017-2022) & (USD/MT) Table 28. Key Manufacturers Idiopathic Pulmonary Fibrosis Drug Plants/Factories Distribution Table 29. Key Manufacturers Idiopathic Pulmonary Fibrosis Drug Area Served Table 30. Date of Key Manufacturers Enter into Idiopathic Pulmonary Fibrosis Drug Market Table 31. Key Manufacturers Idiopathic Pulmonary Fibrosis Drug Product Type Table 32. Mergers & Acquisitions, Expansion Plans Table 33. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Type (2017-2022) Table 34. Global Idiopathic Pulmonary Fibrosis Drug Sales Share by Type (2017-2022) Table 35. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) Market Share by Type (2017-2022) Table 36. Global Idiopathic Pulmonary Fibrosis Drug Price (K MT) by Type (2017-2022) Table 37. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Type (2023-2028) Table 38. Global Idiopathic Pulmonary Fibrosis Drug Sales Share by Type (2023-2028) Table 39. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) Market Share by Type (2023-2028) Table 40. Global Idiopathic Pulmonary Fibrosis Drug Revenue Share by Type (2023-2028) Table 41. Global Idiopathic Pulmonary Fibrosis Drug Price (K MT) by Type (2023-2028) Table 42. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Application (2017-2022) Table 43. Global Idiopathic Pulmonary Fibrosis Drug Sales Share by Application (2017-2022) Table 44. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) Market Share by Application (2017-2022) Table 45. Global Idiopathic Pulmonary Fibrosis Drug Price (K MT) by Application (2017-2022) Table 46. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Application (2023-2028) Table 47. Global Idiopathic Pulmonary Fibrosis Drug Sales Share by Application (2023-2028) Table 48. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) Market Share by Application (2023-2028) Table 49. Global Idiopathic Pulmonary Fibrosis Drug Revenue Share by Application (2023-2028) Table 50. Global Idiopathic Pulmonary Fibrosis Drug Price (K MT) by Application (2023-2028) Table 51. North America Idiopathic Pulmonary Fibrosis Drug Sales by Company (2017-2022) & (K MT) Table 52. North America Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2017-2022) Table 53. North America Idiopathic Pulmonary Fibrosis Drug Revenue by Company (2017-2022) & (US$ Million) Table 54. North America Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Company (2017-2022) Table 55. North America Idiopathic Pulmonary Fibrosis Drug Sales by Type (2017-2022) & (K MT) Table 56. North America Idiopathic Pulmonary Fibrosis Drug Sales by Type (2023-2028) & (K MT) Table 57. North America Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2017-2022) & (US$ Million) Table 58. North America Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2023-2028) & (US$ Million) Table 59. North America Idiopathic Pulmonary Fibrosis Drug Sales by Application (2017-2022) & (K MT) Table 60. North America Idiopathic Pulmonary Fibrosis Drug Sales by Application (2023-2028) & (K MT) Table 61. North America Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2017-2022) & (US$ Million) Table 62. North America Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2023-2028) & (US$ Million) Table 63. North America Idiopathic Pulmonary Fibrosis Drug Sales by Country (2017-2022) & (K MT) Table 64. North America Idiopathic Pulmonary Fibrosis Drug Sales by Country (2023-2028) & (K MT) Table 65. North America Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2017-2022) & (US$ Million) Table 66. North America Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2023-2028) & (US$ Million) Table 67. Europe Idiopathic Pulmonary Fibrosis Drug Sales by Company (2017-2022) & (K MT) Table 68. Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2017-2022) Table 69. Europe Idiopathic Pulmonary Fibrosis Drug Revenue by Company (2017-2022) & (US$ Million) Table 70. Europe Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Company (2017-2022) Table 71. Europe Idiopathic Pulmonary Fibrosis Drug Sales by Type (2017-2022) & (K MT) Table 72. Europe Idiopathic Pulmonary Fibrosis Drug Sales by Type (2023-2028) & (K MT) Table 73. Europe Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2017-2022) & (US$ Million) Table 74. Europe Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2023-2028) & (US$ Million) Table 75. Europe Idiopathic Pulmonary Fibrosis Drug Sales by Application (2017-2022) & (K MT) Table 76. Europe Idiopathic Pulmonary Fibrosis Drug Sales by Application (2023-2028) & (K MT) Table 77. Europe Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2017-2022) & (US$ Million) Table 78. Europe Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2023-2028) & (US$ Million) Table 79. Europe Idiopathic Pulmonary Fibrosis Drug Sales by Country (2017-2022) & (K MT) Table 80. Europe Idiopathic Pulmonary Fibrosis Drug Sales by Country (2023-2028) & (K MT) Table 81. Europe Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2017-2022) & (US$ Million) Table 82. Europe Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2023-2028) & (US$ Million) Table 83. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales by Company (2017-2022) & (K MT) Table 84. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2017-2022) Table 85. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue by Company (2017-2022) & (US$ Million) Table 86. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Company (2017-2022) Table 87. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales by Type (2017-2022) & (K MT) Table 88. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales by Type (2023-2028) & (K MT) Table 89. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2017-2022) & (US$ Million) Table 90. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2023-2028) & (US$ Million) Table 91. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales by Application (2017-2022) & (K MT) Table 92. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales by Application (2023-2028) & (K MT) Table 93. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2017-2022) & (US$ Million) Table 94. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2023-2028) & (US$ Million) Table 95. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales by Region (2017-2022) & (K MT) Table 96. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales by Region (2023-2028) & (K MT) Table 97. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue by Region (2017-2022) & (US$ Million) Table 98. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue by Region (2023-2028) & (US$ Million) Table 99. Latin America Idiopathic Pulmonary Fibrosis Drug Sales by Company (2017-2022) & (K MT) Table 100. Latin America Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2017-2022) Table 101. Latin America Idiopathic Pulmonary Fibrosis Drug Revenue by Company (2017-2022) & (US$ Million) Table 102. Latin America Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Company (2017-2022) Table 103. Latin America Idiopathic Pulmonary Fibrosis Drug Sales by Type (2017-2022) & (K MT) Table 104. Latin America Idiopathic Pulmonary Fibrosis Drug Sales by Type (2023-2028) & (K MT) Table 105. Latin America Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2017-2022) & (US$ Million) Table 106. Latin America Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2023-2028) & (US$ Million) Table 107. Latin America Idiopathic Pulmonary Fibrosis Drug Sales by Application (2017-2022) & (K MT) Table 108. Latin America Idiopathic Pulmonary Fibrosis Drug Sales by Application (2023-2028) & (K MT) Table 109. Latin America Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2017-2022) & (US$ Million) Table 110. Latin America Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2023-2028) & (US$ Million) Table 111. Latin America Idiopathic Pulmonary Fibrosis Drug Sales by Country (2017-2022) & (K MT) Table 112. Latin America Idiopathic Pulmonary Fibrosis Drug Sales by Country (2023-2028) & (K MT) Table 113. Latin America Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2017-2022) & (US$ Million) Table 114. Latin America Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2023-2028) & (US$ Million) Table 115. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales by Company (2017-2022) & (K MT) Table 116. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2017-2022) Table 117. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue by Company (2017-2022) & (US$ Million) Table 118. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Company (2017-2022) Table 119. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales by Type (2017-2022) & (K MT) Table 120. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales by Type (2023-2028) & (K MT) Table 121. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2017-2022) & (US$ Million) Table 122. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue by Type (2023-2028) & (US$ Million) Table 123. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales by Application (2017-2022) & (K MT) Table 124. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales by Application (2023-2028) & (K MT) Table 125. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2017-2022) & (US$ Million) Table 126. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue by Application (2023-2028) & (US$ Million) Table 127. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales by Country (2017-2022) & (K MT) Table 128. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales by Country (2023-2028) & (K MT) Table 129. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2017-2022) & (US$ Million) Table 130. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue by Country (2023-2028) & (US$ Million) Table 131. Roche Corporation Information Table 132. Roche Description and Overview Table 133. Roche Idiopathic Pulmonary Fibrosis Drug Sales (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2017-2022) Table 134. Roche Idiopathic Pulmonary Fibrosis Drug Product and Services Table 135. Roche Idiopathic Pulmonary Fibrosis Drug SWOT Analysis Table 136. Roche Recent Developments Table 137. Boehringer Ingelheim Corporation Information Table 138. Boehringer Ingelheim Description and Overview Table 139. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Drug Sales (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2017-2022) Table 140. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Drug Product and Services Table 141. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Drug SWOT Analysis Table 142. Boehringer Ingelheim Recent Developments Table 143. Beijing Continent Pharmaceutical Corporation Information Table 144. Beijing Continent Pharmaceutical Description and Overview Table 145. Beijing Continent Pharmaceutical Idiopathic Pulmonary Fibrosis Drug Sales (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2017-2022) Table 146. Beijing Continent Pharmaceutical Idiopathic Pulmonary Fibrosis Drug Product and Services Table 147. Beijing Continent Pharmaceutical Idiopathic Pulmonary Fibrosis Drug SWOT Analysis Table 148. Beijing Continent Pharmaceutical Recent Developments Table 149. Cipla Corporation Information Table 150. Cipla Description and Overview Table 151. Cipla Idiopathic Pulmonary Fibrosis Drug Sales (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2017-2022) Table 152. Cipla Idiopathic Pulmonary Fibrosis Drug Product and Services Table 153. Cipla Idiopathic Pulmonary Fibrosis Drug SWOT Analysis Table 154. Cipla Recent Developments Table 155. Shionogi Corporation Information Table 156. Shionogi Description and Overview Table 157. Shionogi Idiopathic Pulmonary Fibrosis Drug Sales (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2017-2022) Table 158. Shionogi Idiopathic Pulmonary Fibrosis Drug Product and Services Table 159. Shionogi Idiopathic Pulmonary Fibrosis Drug SWOT Analysis Table 160. Shionogi Recent Developments Table 161. Key Raw Materials Lists Table 162. Raw Materials Key Suppliers Lists Table 163. Idiopathic Pulmonary Fibrosis Drug Distributors List Table 164. Idiopathic Pulmonary Fibrosis Drug Customers List Table 165. Research Programs/Design for This Report Table 166. Key Data Information from Secondary Sources Table 167. Key Data Information from Primary Sources List of Figures Figure 1. Idiopathic Pulmonary Fibrosis Drug Product Picture Figure 2. Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type in 2021 & 2028 Figure 3. Glucocorticoid Product Picture Figure 4. Immunosuppressive Agent Product Picture Figure 5. Others Product Picture Figure 6. Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application in 2021 & 2028 Figure 7. Hospital Use Case Figure 8. Clinic Use Case Figure 9. Others Use Case Figure 10. Idiopathic Pulmonary Fibrosis Drug Report Years Considered Figure 11. Global Idiopathic Pulmonary Fibrosis Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 12. Global Idiopathic Pulmonary Fibrosis Drug Market Size 2017-2028 (US$ Million) Figure 13. Global Idiopathic Pulmonary Fibrosis Drug Sales (2017-2022) & (K MT) Figure 14. Global Idiopathic Pulmonary Fibrosis Drug Market Size Market Share by Region: 2021 VS 2028 Figure 15. Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Region (2017-2022) Figure 16. Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Region in 2021 Figure 17. Global Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Region in 2017 VS 2021 Figure 18. Global Idiopathic Pulmonary Fibrosis Drug Sales Share by Manufacturers in 2021 Figure 19. The 5 and 10 Largest Manufacturers in the World: Market Share by Idiopathic Pulmonary Fibrosis Drug Sales in 2021 Figure 20. Idiopathic Pulmonary Fibrosis Drug Revenue Share by Manufacturers in 2021 Figure 21. Idiopathic Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 22. Global Idiopathic Pulmonary Fibrosis Drug Revenue Share by Type (2017-2022) Figure 23. Global Idiopathic Pulmonary Fibrosis Drug Revenue Growth Rate by Type in 2017 & 2021 Figure 24. Global Idiopathic Pulmonary Fibrosis Drug Revenue Share by Application (2017-2022) Figure 25. Global Idiopathic Pulmonary Fibrosis Drug Revenue Growth Rate by Application in 2017 & 2021 Figure 26. North America Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2017-2028) Figure 27. North America Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Type (2017-2028) Figure 28. North America Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2017-2028) Figure 29. North America Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Application (2017-2028) Figure 30. North America Idiopathic Pulmonary Fibrosis Drug Sales Share by Country (2017-2028) Figure 31. North America Idiopathic Pulmonary Fibrosis Drug Revenue Share by Country (2017-2028) Figure 32. U.S. Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 33. Canada Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 34. Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2017-2028) Figure 35. Europe Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Type (2017-2028) Figure 36. Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2017-2028) Figure 37. Europe Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Application (2017-2028) Figure 38. Europe Idiopathic Pulmonary Fibrosis Drug Sales Share by Country (2017-2028) Figure 39. Europe Idiopathic Pulmonary Fibrosis Drug Revenue Share by Country (2017-2028) Figure 40. Germany Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 41. France Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 42. U.K. Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 43. Italy Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 44. Russia Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 45. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2017-2028) Figure 46. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Type (2017-2028) Figure 47. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2017-2028) Figure 48. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Application (2017-2028) Figure 49. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Sales Share by Region (2017-2028) Figure 50. Asia Pacific Idiopathic Pulmonary Fibrosis Drug Revenue Share by Region (2017-2028) Figure 51. China Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 52. Japan Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 53. South Korea Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 54. India Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 55. Australia Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 56. Taiwan Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 57. Indonesia Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 58. Thailand Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 59. Malaysia Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 60. Philippines Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 61. Vietnam Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 62. Latin America Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2017-2028) Figure 63. Latin America Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Type (2017-2028) Figure 64. Latin America Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2017-2028) Figure 65. Latin America Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Application (2017-2028) Figure 66. Latin America Idiopathic Pulmonary Fibrosis Drug Sales Share by Country (2017-2028) Figure 67. Latin America Idiopathic Pulmonary Fibrosis Drug Revenue Share by Country (2017-2028) Figure 68. Mexico Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 69. Brazil Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 70. Argentina Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 71. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2017-2028) Figure 72. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Type (2017-2028) Figure 73. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2017-2028) Figure 74. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Application (2017-2028) Figure 75. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Sales Share by Country (2017-2028) Figure 76. Middle East and Africa Idiopathic Pulmonary Fibrosis Drug Revenue Share by Country (2017-2028) Figure 77. Turkey Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 78. Saudi Arabia Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 79. U.A.E Idiopathic Pulmonary Fibrosis Drug Revenue (2017-2028) & (US$ Million) Figure 80. Idiopathic Pulmonary Fibrosis Drug Value Chain Figure 81. Idiopathic Pulmonary Fibrosis Drug Production Process Figure 82. Channels of Distribution Figure 83. Distributors Profiles Figure 84. Bottom-up and Top-down Approaches for This Report Figure 85. Data Triangulation Figure 86. Key Executives Interviewed

Roche Boehringer Ingelheim Beijing Continent Pharmaceutical Cipla Shionogi